ACC 2018 | Flu Vaccination Reduces Mortality in Heart Failure Hospitalizations

Heart failure patients vaccinated against influenza are at a significantly lower risk of dying, both during flu season and outside of it.

Patients with heart failure vaccinated had a 48% lower risk of death during influenza season and a 21% lower risk during the rest of the year.

Dr. Fukuta, lead investigator in this study, explained that flu vaccination of heart failure patients in Japan is not formally recommended. Larger-scale and adequately powered randomized controlled trials, such as INVESTED, will provide a definitive answer.

At the moment, with some inconsistent results, we must settle for this meta-analysis led by Dr. Fukuta, which includes 5 observational studies involving a total of 78,882 patients with heart failure. The age of patients ranged from 64 to 75 years old, and study follow-up was between 1 and 4 years.


Read also: ACC 2018 | Risk of MI in Non-Cardiac Surgeries.


There are physiopathologic reasons supporting vaccination, such as the fact that respiratory infections (including influenza) are the precipitating cause of heart failure and are associated with increased mortality. If vaccination reduces the incidence and/or severity of these respiratory infections, it will prevent heart failure exacerbations, hospitalization, and associated mortality.

Furthermore, vaccination reduces the risk of cardiovascular events, including infarction and unstable angina, in patients with coronary artery disease. There are studies showing a sixfold higher risk of infarction in the week after a flu diagnosis. In such cases, physiopathology is probably related to inflammation.

Original title: The Effect of Influenza Vaccination on Mortality and Hospitalization in Patients with Heart Failure: A Meta-Analysis.

Presenter: Fukuta H.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...

TCT 2025 | ANDES Trial: Short-Term DOAC vs. DAPT After Percutaneous Left Atrial Appendage Occlusion

Percutaneous left atrial appendage occlusion (LAAO) is an established alternative to chronic anticoagulation in patients with non-valvular atrial fibrillation (AFib). A clinically relevant complication...

TCT 2025 | STORM-PE: Mechanical Thrombectomy with Penumbra Lightning+AC vs. Anticoagulation Alone in Intermediate-High Risk PE

Intermediate-high risk pulmonary embolism (PE) remains a therapeutic challenge. Anticoagulation is still the standard treatment, albeit with limited efficacy in patients with right ventricular...

TCT 2025 | SUMMIT-MAC: Transcatheter Mitral Valve Replacement with the Tendyne System in Patients with Severe Annular Calcification

The prospective, multicenter SUMMIT-MAC study evaluated the safety and efficacy of transcatheter mitral valve replacement (TMVR) using the Tendyne system in patients with severe...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Hypertriglyceridemia as Key Factor to Abdominal Aortic Aneurysm Development and Rupture: Genetic and Experimental Evidence

Abdominal aortic aneurysm (AAA) is a deadly vascular disease with no effective drug treatment, and risk of rupture reaching up to 80%. Even though...

CALIPSO: Calcified Lesions and Use of OCT

Percutaneous coronary intervention (PCI) in calcified lesions remains one of the most challenging scenarios in daily practice, as these lesions are often accompanied by...

Atrial Fibrillation and Chronic Kidney Disease: Outcomes of Different Stroke Prevention Strategies

Atrial fibrillation (AF) affects approximately 1 in every 4 patients with end-stage renal disease (ESRD). This population carries a high burden of comorbidities and...